Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2022; 76(1): 57–59. doi: 10.48095/ccgh202257.

Remsima SC 120 mg – a new generation of biosimilar drugs

Milan Lukáš1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Remsima; summary of product characteristics. 2021 [online]. Available from: https: //
2. Schreiber S, D’Haens G, Cummings F et al. Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease. Post hoc analysis of pre-post switch outcomes from multicentre, randomized, controlled pivotal trial. UEGW 2021, P0472.
3. Lukáš M. První generace biologických léčiv anti-TNF alfa monoklonální protilátky. In: Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galén 2019.
4. Kennedy NA, Heap GA, Green HD et al. Predictors of anti-TNF therapy failure in anti-TNF naive patients with active luminal Crohn’s disease. A prospective multicentre cohort study. Lancet Gastroenterol Hepatol 2019; 4(5): 341–353. doi: 10.1016/S2468-1253(19)30012-3.

Credited self-teaching test